Navigation Links
Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
Date:10/19/2011

THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the Company's Global Commercial Operations.

Hooper, 56, joins Amgen after sixteen years at Bristol-Myers Squibb Company (BMS) where he was most recently senior vice president, Commercial Operations and president, United States, Japan and Intercontinental.  Hooper's broad commercial operations experience includes running the BMS commercial business in North America, Asia, Middle East, Africa, South America and Europe.  

"As we continue to grow, Tony's track record of delivering results and his passion for serving patients across the globe make him an outstanding addition to Amgen's leadership team," Bradway said.

"It's a privilege to join Amgen, a Company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses," said Hooper. "I am looking forward to bringing my global commercial experience to Amgen as it moves to implement its strategic vision for growth and international expansion."

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains commit
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Neogen Corporation (Nasdaq: NEOG ) advised ... revenue from new rodenticide research are premature. In its ... July 22, 2014, Neogen,s CEO commented about several new ... "It was my intent Tuesday at our conference ... new type of rodenticide, but certainly not to give ...
(Date:7/24/2014)... Md. , July 24, 2014  Spherix Incorporated ... the fostering and monetization of intellectual property, today announced ... the period ending June 30, 2014 on Monday, August ... call at 10 a.m. ET on Monday, August 18, ... be led by the company,s CEO, Anthony Hayes ...
(Date:7/23/2014)... (UAE) (PRWEB) July 23, 2014 International ... recently announced that its biobanking project, Provia Laboratories ... to its growing Advisory Board. Scott Wolf , ... to have Dr. Vaught onboard with Provia’s ever-expanding Advisory ... expertise that Provia’s management team brings to this field, ...
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- Think Drinks are a neuroscience-backed drink ... term. They are the first functional focus beverage to ... an alternative to the temporary fix associated with energy ... July 29, 2014, with hopes to raise $50,000 over ... - http://photos.prnewswire.com/prnh/20140723/129697 Think Drinks ...
Breaking Biology Technology:Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2
... across the developing world could reduce the environmental impact ... India, writing today in the Inderscience publication, International Journal ... in the developing world are encouraged to compost our ... compost bin and not all of us are willing ...
... sustainable solar energy by imitating nature. Nanotechnology researchers like ... nanoscale materials that mimic the architecture of grass and ... , A new podcast looks at how Dr. Lewis ... tiny nanoparticles into simple, inexpensive everyday products like house ...
... Lee Biosolutions, Inc, (http://www.leebio.com ) announces the ... human renin from human kidney. Human Renin ... blood pressure,and electrolyte homeostasis and therefore is of ... renin are of importance for the,development of hypertension ...
Cached Biology Technology:Landfill mining reduces environmental impact of growing waste 2
(Date:7/24/2014)... that characterize sustainable university and college programs designed ... teachers. Specifically, one or more faculty members who ... with institutional motivation and commitment can ensure that ... Math (STEM) teacher shortages are especially acute in ... institutions seeking to increase the number of STEM ...
(Date:7/24/2014)... TORONTO, June 24, 2014 Some sticky research out ... fight against a certain species of toxic grass fungus: ... this month,s Biology Letters , "Ungulate saliva inhibits ... when applied to red fescue grass (which hosts a ... results in slower fungus growth and less toxicity. , ...
(Date:7/24/2014)... 24, 2014(BRONX, NY)Researchers at Albert Einstein College of ... from The Michael J. Fox Foundation for Parkinson,s Research ... for Parkinson,s disease. This drug discovery project will test ... goal of developing a drug that acts on an ... therapies for Parkinson,s help many people manage their symptoms, ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... While there is no cure for lingering viral infections ... Princeton University suggests it may be possible to deactivate ... switch. , Princeton scientists Leor Weinberger and Thomas ... which human immunodeficiency virus (HIV) and other viruses transition ...
... have found a new pathway by which cells change their ... Institutes of Health, they plan to fill in the details ... could lead to a better understanding of the importance of ... Cells must interact with each other to produce system responses, ...
... University Massey Cancer Center today presented preclinical research ... meeting suggesting the potential of a new combination ... , In this study, led by Steven Grant, ... between bortezomib and romidepsin (Gloucester Pharmaceuticals) and bortezomib ...
Cached Biology News:Scientists find potential 'off-switch' for HIV virus 2Scientists find potential 'off-switch' for HIV virus 3Scientists find potential 'off-switch' for HIV virus 4New molecular pathway could reveal how cells stick together 2
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
CBF-B (G-2)...
... B Receptor Like Protein 2 ... (ETBR-LP-2) has been reported in human ... human brain and colon libraries. ... the amino acid sequence is considered ...
Biology Products: